BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics


BiondVax Pharmaceuticals Ltd. (BVXV): $9.76

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BVXV Stock Price Chart Interactive Chart >

Price chart for BVXV

BVXV Price/Volume Stats

Current price $9.76 52-week high $34.90
Prev. close $9.76 52-week low $5.34
Day low $9.02 Volume 25,100
Day high $9.90 Avg. volume 42,388
50-day MA $8.02 Dividend yield N/A
200-day MA $11.63 Market Cap 13.99M

BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio


Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.


BVXV Latest News Stream


Event/Time News Detail
Loading, please wait...

BVXV Latest Social Stream


Loading social stream, please wait...

View Full BVXV Social Stream

Latest BVXV News From Around the Web

Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.

BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy

Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled placeboBiondVax’s nanosized antibodies (NanoAbs) are being formulated as a convenient self‑administered, at-home, inhaled COVID-19 therapy First-in-human Phase 1/2a clinical trial planned for 2023The COVID-19 therapy is BiondVax’s first in a new pipeline of innovative alpaca-derived NanoAb

Yahoo | November 29, 2022

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference.

Yahoo | November 21, 2022

BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences

JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, congratulates the company’s co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (MPI), on being

Yahoo | November 15, 2022

BiondVax Announces Plan to Implement ADS Ratio Change

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, announces today that it plans to effect a ratio change of the Company’s American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS re

Yahoo | November 10, 2022

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer, BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place Nov

Yahoo | November 3, 2022

Read More 'BVXV' Stories Here

BVXV Price Returns

1-mo 19.17%
3-mo -7.05%
6-mo -27.70%
1-year -45.78%
3-year -83.43%
5-year -82.29%
YTD -58.47%
2021 -16.37%
2020 -69.75%
2019 94.76%
2018 -11.01%
2017 60.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6326 seconds.